The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase 2, multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as 1L therapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ; DisTinGuish).
 
Keun-Wook Lee
Honoraria - Boryung; JW Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; Sanofi/Aventis; Vifor Pharma
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); GC Pharma (Inst); Genome & Company (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
 
Markus H. Moehler
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Pierre Fabre; Roche/Genentech; Sanofi; Servier
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; BMS; Lilly; Merck Serono; MSD; Pfizer; Roche; SERVIER; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; ESMO; German Cancer Society; Merck Serono; MSD; Roche
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Roche (Inst)
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Arcus Biosciences; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; QED Therapeutics; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Hope Elizabeth Uronis
Employment - GeneCentric (I)
Stock and Other Ownership Interests - GeneCentric (I)
Consulting or Advisory Role - AstraZeneca
Research Funding - Adaptimmune; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Merck (Inst)
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
In-Ho Kim
No Relationships to Disclose
 
Byoung Yong Shim
Consulting or Advisory Role - Takeda
Research Funding - Yuhan
 
Sun Jin Sym
No Relationships to Disclose
 
Rachel A Altura
Employment - Leap Therapeutics; Merck
Stock and Other Ownership Interests - Leap Therapeutics; Merck
Travel, Accommodations, Expenses - Merck
 
Melissa C Stilian
Employment - Kiniksa; Leap Therapeutics
Stock and Other Ownership Interests - Kiniksa; Leap Therapeutics
 
Elizabeth C Parker
Employment - Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics
Travel, Accommodations, Expenses - Leap Therapeutics
 
Samuel J Klempner
Stock and Other Ownership Interests - Nuvalent, Inc.; TP Therapeutics
Honoraria - Natera
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Exact Sciences; Lilly; Merck; Mersana; Novartis; Pieris Pharmaceuticals; Sanofi/Aventis
Research Funding - BeiGene (Inst); Leap Therapeutics (Inst); Silverback Therapeutics (Inst)
Other Relationship - NCCN